期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 3, 期 114, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3003149
关键词
-
资金
- Swedish Research Council
- Swedish Cancer Foundation
- Karolinska Institute Foundation
- Karolinska Institute
- Torsten Soderbergs Foundation
- European Union of Metoxia [222741]
- European Research Council [250021]
- U.S. NIH [R01 CA118764-01, P01 CA45548]
- ImClone Systems Inc./Eli Lilly
- GlaxoSmithKline
- European Research Council (ERC) [250021] Funding Source: European Research Council (ERC)
Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据